¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ Á¦13ȸ Nephrology Board Review Course 2019 : 2019-02-09

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÅÀåÇÐȸ Á¦13ȸ Nephrology Board Review Course 2019 : 2019-02-09
±³À°ÀÏÀÚ : 2019-02-09
±³À°Àå¼Ò : ¼­¿ï, ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ(¿ë»ê±¸ ÀÓÁ¤·Î 26 ¼ÒÀç)  
±³À°ÁÖÁ¦ : Á¦13ȸ Nephrology Board Review Course 2019
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : »ç¹«±¹ ¿¬¶ôó
¿¬¶ôó : 02-3486-8736  
À̸ÞÀÏ : ksn@ksn.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 09:10~09:40 Metabolic acidosis of CKD: pathogenesis, consequences, and treatment  Áֱǿí(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 09:40~10:10 Hypokalemia: clinical perspectives on endocrine connections  ±è¼ö¿Ï(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 10:10~10:40 Dysnatremia in patients with neurologic disorders  ±è¼¼Áß(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 10:50~11:15 Pathology and mechanisms of glomerular diseases  ÀÓ¹üÁø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 11:15~11:40 Nephrotic syndrome (focusing on MCD and FSGS)  ±èÈ¿»ó(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 11:40~12:05 Membranous nephropathy (idiopathic and secondary)  ¿ÀÁöÀº(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 13:05~13:30 Membranoproliferative glomerulonephritis and C3 glomerulopathy  ¿À¼¼¿ø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 13:30~13:55 Treatment of IgA nephropathy based on pathologic classification  ÀÌÇÏÁ¤(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 13:55~14:20 Paraprotein-related kidney disease  ÀÌÁ¤Àº(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 14:30~14:55 Effect of low salt and protein diet in CKD progression  À̼º¿ì(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 14:55~15:20 Optimal therapeutic strategies for CKD-MBD  Á¤Áö¿ë(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 15:20~15:45 Diabetic kidney disease (current and future strategies)  ÇѽÂÇõ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 15:45~16:10 Hyperuricemia in CKD  ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 16:10~16:35 Medical management of obesity in CKD  ±Ç¼ø±æ(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 16:35~17:00 Update on renovascular disease  ±èÅÂÈñ(ÀÎÁ¦ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ Á¦13ȸ Nephrology Board Review Course 2019 : 2019-02-09""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѽÅÀåÇÐȸ Á¦13ȸ Nephrology Board Review Course 2019 : 2019-02-10
´ÙÀ½±Û °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø °¡Å縯´ëÇб³ »êºÎÀΰúÇб³½Ç ¿¬¼ö°­Á : 2019-01-27
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 0 74 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 0 32 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 30 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 15 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 16 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 18 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 26 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 14 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 12 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 22 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 16 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 16 2024-04-17
20455 ¼­¿ï Á¦7Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 24 2024-04-17
20454 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°­Á : 2024-05-18 0 23 2024-04-17
20453 ¼­¿ï 2024³â ´ëÇÑ¿¬ÇÏÀå¾ÖÇÐȸ Á¦14ȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 16 2024-04-17
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷